FDA Comirnaty Insert:
“Available data on COMIRNATY administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.“Source
“Q: Can pregnant or breastfeeding women receive Pfizer-BioNTech COVID-19 Vaccine?
A: While there have been no specific studies in these groups, there is no contraindication to receipt of the vaccine for pregnant or breastfeeding women. Pregnant or breastfeeding women should discuss potential benefits and risks of vaccination with their healthcare provider.”Source
“Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.”Study: PFIZER-BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS OF PIVOTAL COVID-19 VACCINE STUDY IN ADOLESCENTS
- The Pfizer trial on pregnant women is ongoing through October 2022 and is only evaluating the vaccination of women who are 24 to 36 weeks pregnant. Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
- Study: Ovarian toxicity of nanoparticles
- Article: THIRTY-FOUR WOMEN REPORT SPONTANEOUS MISCARRIAGES OR STILLBIRTHS AFTER RECEIVING COVID VACCINE
- Article: A Lack of Safety Data in Pregnant Females as Another Example of Why Vaccines Should Not be Mandated
- Article: Leaked Pfizer Study: Vax Particles Massively Build Up In Ovaries
- Article: Inventor of mRNA Technology: Vaccine Causes Lipid Nanoparticles to Accumulate in ‘High Concentrations’ in Ovaries
- Article: Pfizer COVID Vaccine Studies Delayed For Pregnant Women, Due to pregnant women being hesitant to join vaccine studies and vaccination guidelines changing, Pfizer vaccine studies have been delayed.
- Video: DR BYRAM BRIDLE – SPIKE PROTEIN IS A DANGEROUS TOXIN The whole spike protein goes into breast milk and there is evidence of bleeding disorders in babies who have been breastfed by vaccinated moms.
- Video: LAURA INGRAHAM: DR. HARVEY RISCH & DR. PETER MCCULLOUGH – THE RISKS OF COVID-19 JABS
- Video: ARE COVID VACCINES TRIGGERING MISCARRIAGES?
There is no data on the health impacts of being vaccinated preconception, in early stages of pregnancy, or what the long-term effects of the child will be in a mother is vaccinated while pregnant.
“Continued monitoring is needed to further assess maternal, pregnancy, neonatal, and childhood outcomes associated with maternal Covid-19 vaccination, including in earlier stages of pregnancy and during the preconception period.”Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons (and these scientists do not even recognize that the only “persons” who are capable of being pregnant are women)
As of October 2020, this was the FDA’s working list of possible adverse events. The people getting the shots did not get this information (informed consent).
You can see all of the slides here.
There are stories like this about breastfeeding babies of mamas who received the vaccine:
And another baby died of a blood clot after her mother received the Johnson & Johnson shot.
In the phase II/III Pfizer trial, there was concern about a pregnant or breastfeeding or soon-to-be pregnant mom being exposed to the “study intervention” (someone who got the shot) by skin contact or inhalation.
The following information is from pages 67-69. Note that SAE stands for “Serious Adverse Event.”
“8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure Exposure to the study intervention under study during pregnancy or breastfeeding and occupational exposure are reportable to Pfizer Safety within 24 hours of investigator awareness.
184.108.40.206. Exposure During Pregnancy An EDP occurs if: • A female participant is found to be pregnant while receiving or after discontinuing study intervention. • A male participant who is receiving or has discontinued study intervention exposes a female partner prior to or around the time of conception. • A female is found to be pregnant while being exposed or having been exposed to study intervention due to environmental exposure. Below are examples of environmental exposure during pregnancy: • A female family member or healthcare provider reports that she is pregnant after having been exposed to the study intervention by inhalation or skin contact. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 Page 68 • A male family member or healthcare provider who has been exposed to the study intervention by inhalation or skin contact then exposes his female partner prior to or around the time of conception. The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The initial information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy). • If EDP occurs in a participant or a participant’s partner, the investigator must report this information to Pfizer Safety on the Vaccine SAE Report Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until 6 months after the last dose of study intervention. • If EDP occurs in the setting of environmental exposure, the investigator must report information to Pfizer Safety using the Vaccine SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccine SAE Report Form is maintained in the investigator site file. Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless preprocedure test findings are conclusive for a congenital anomaly and the findings are reported). Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to Pfizer Safety as SAEs follows: • Spontaneous abortion including miscarriage and missed abortion; • Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 Page 69 Additional information regarding the EDP may be requested by the sponsor. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.
220.127.116.11. Exposure During Breastfeeding An exposure during breastfeeding occurs if: • A female participant is found to be breastfeeding while receiving or after discontinuing study intervention. • A female is found to be breastfeeding while being exposed or having been exposed to study intervention (ie, environmental exposure). An example of environmental exposure during breastfeeding is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by inhalation or skin contact. The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The information must be reported using the Vaccine SAE Report Form. When exposure during breastfeeding occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study, so the information is not recorded on a CRF. However, a copy of the completed Vaccine SAE Report Form is maintained in the investigator site file.”